IONIS

A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Study Type  : Interventional  (Clinical Trial)
Actual Enrollment  : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double Masked
Primary Purpose: Treatment
Official Title: A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of ISIS 696844, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary (GA) to Age-Related Macular Degeneration (AMD)
Actual Study Start Date  : March 16, 2018
Actual Primary Completion Date  : October 10, 2018
Actual Study Completion Date  : October 10, 2018

Related Publications

Our Affiliates